chemieunternehmen.com

Evotec AG: Results of pre-clinical studies lead to reduction in revenues, nevertheless profitable and more than EUR 90 m cash for 2013 confirmed

Report Content

Issue: *
Copyright Infringement Spam Invalid Contents Broken Links

Your Name: *

Your Email: *

Details: *

Submit Report

Evotec AG today announced that it is adjusting its guidance regarding Group revenues. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/evotec-ag-results-of-pre-clinical-studies-lead-to-reduction-in-revenues-nevertheless-profitable-and-more-than-eur-90-m-cash-for-2013-confirmed-5612

Auch interessant:

• Evotec SE fiscal year 2021 results: "Setting the…
• Evotec SE reports results for the first quarter 2021 and…
• Evotec-partner STORM Therapeutics to present the discovery…
• Evotec SE fiscal year 2020 results: Gaining speed on the…
• Evotec SE reports results for the first nine months 2022 and
• Evotec SE reports results for the first quarter 2022 and…